Des soins de soutien, comme l'hydratation et le monitoring, sont essentiels.
Soins de soutienHydratation
#5
Y a-t-il des traitements spécifiques pour les effets chroniques ?
Les traitements des effets chroniques incluent la réhabilitation et le suivi médical.
RéhabilitationSuivi médical
Complications
5
#1
Quelles complications peuvent survenir après exposition ?
Des complications incluent des troubles hépatiques, rénaux et neurologiques.
ComplicationsTroubles hépatiques
#2
Y a-t-il des risques de cancer associés ?
Une exposition prolongée peut augmenter le risque de certains cancers.
CancerExposition prolongée
#3
Comment les complications sont-elles surveillées ?
Des examens médicaux réguliers et des tests de fonction organique sont nécessaires.
Surveillance médicaleTests de fonction
#4
Les complications peuvent-elles être réversibles ?
Certaines complications peuvent être réversibles avec un traitement précoce.
Complications réversiblesTraitement précoce
#5
Quels sont les effets à long terme possibles ?
Les effets à long terme peuvent inclure des troubles chroniques et des déficits fonctionnels.
Effets à long termeTroubles chroniques
Facteurs de risque
5
#1
Qui est le plus à risque d'exposition ?
Les travailleurs dans l'industrie chimique et les laboratoires sont les plus à risque.
TravailleursIndustrie chimique
#2
Quels environnements augmentent le risque ?
Les environnements de travail mal ventilés et non sécurisés augmentent le risque.
Environnements de travailVentilation
#3
Y a-t-il des facteurs génétiques impliqués ?
Des facteurs génétiques peuvent influencer la susceptibilité à la toxicité.
Facteurs génétiquesSusceptibilité
#4
Comment l'âge influence-t-il le risque ?
Les personnes âgées peuvent être plus vulnérables aux effets toxiques.
ÂgeVulnérabilité
#5
Les antécédents médicaux jouent-ils un rôle ?
Oui, des antécédents de maladies hépatiques ou rénales augmentent le risque.
Antécédents médicauxMaladies hépatiques
{
"@context": "https://schema.org",
"@graph": [
{
"@type": "MedicalWebPage",
"name": "1,1',1''-Phosphoryltriaziridine : Questions médicales les plus fréquentes",
"headline": "1,1',1''-Phosphoryltriaziridine : Comprendre les symptômes, diagnostics et traitements",
"description": "Guide complet et accessible sur les 1,1',1''-Phosphoryltriaziridine : explications, diagnostics, traitements et prévention. Information médicale validée destinée aux patients.",
"datePublished": "2024-07-09",
"dateModified": "2025-04-05",
"inLanguage": "fr",
"medicalAudience": [
{
"@type": "MedicalAudience",
"name": "Grand public",
"audienceType": "Patient",
"healthCondition": {
"@type": "MedicalCondition",
"name": "1,1',1''-Phosphoryltriaziridine"
},
"suggestedMinAge": 18,
"suggestedGender": "unisex"
},
{
"@type": "MedicalAudience",
"name": "Médecins",
"audienceType": "Physician",
"geographicArea": {
"@type": "AdministrativeArea",
"name": "France"
}
},
{
"@type": "MedicalAudience",
"name": "Chercheurs",
"audienceType": "Researcher",
"geographicArea": {
"@type": "AdministrativeArea",
"name": "International"
}
}
],
"reviewedBy": {
"@type": "Person",
"name": "Dr Olivier Menir",
"jobTitle": "Expert en Médecine",
"description": "Expert en Médecine, Optimisation des Parcours de Soins et Révision Médicale",
"url": "/static/pages/docteur-olivier-menir.html",
"alumniOf": {
"@type": "EducationalOrganization",
"name": "Université Paris Descartes"
}
},
"isPartOf": {
"@type": "MedicalWebPage",
"name": "Aziridines",
"url": "https://questionsmedicales.fr/mesh/D001388",
"about": {
"@type": "MedicalCondition",
"name": "Aziridines",
"code": {
"@type": "MedicalCode",
"code": "D001388",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "D03.383.097.217"
}
}
},
"hasPart": [
{
"@type": "MedicalWebPage",
"name": "Thiotépa",
"alternateName": "Thiotepa",
"url": "https://questionsmedicales.fr/mesh/D013852",
"about": {
"@type": "MedicalCondition",
"name": "Thiotépa",
"code": {
"@type": "MedicalCode",
"code": "D013852",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "D03.383.097.217.935.960"
}
}
}
],
"about": {
"@type": "MedicalCondition",
"name": "1,1',1''-Phosphoryltriaziridine",
"alternateName": "Triethylenephosphoramide",
"code": {
"@type": "MedicalCode",
"code": "D013721",
"codingSystem": "MeSH"
}
},
"author": [
{
"@type": "Person",
"name": "Liusheng Huang",
"url": "https://questionsmedicales.fr/author/Liusheng%20Huang",
"affiliation": {
"@type": "Organization",
"name": "Drug Research Unit, Department of Clinical Pharmacy, University of California San Francisco, USA."
}
},
{
"@type": "Person",
"name": "Beth Apsel Winger",
"url": "https://questionsmedicales.fr/author/Beth%20Apsel%20Winger",
"affiliation": {
"@type": "Organization",
"name": "Department of Pediatrics, University of California San Francisco."
}
},
{
"@type": "Person",
"name": "Vincent Cheah",
"url": "https://questionsmedicales.fr/author/Vincent%20Cheah",
"affiliation": {
"@type": "Organization",
"name": "Drug Research Unit, Department of Clinical Pharmacy, University of California San Francisco, USA."
}
},
{
"@type": "Person",
"name": "David Gingrich",
"url": "https://questionsmedicales.fr/author/David%20Gingrich",
"affiliation": {
"@type": "Organization",
"name": "Drug Research Unit, Department of Clinical Pharmacy, University of California San Francisco, USA."
}
},
{
"@type": "Person",
"name": "Florence Marzan",
"url": "https://questionsmedicales.fr/author/Florence%20Marzan",
"affiliation": {
"@type": "Organization",
"name": "Drug Research Unit, Department of Clinical Pharmacy, University of California San Francisco, USA."
}
}
],
"citation": [
{
"@type": "ScholarlyArticle",
"name": "Evaluation of bone mineral density and bone turnover in children on anticoagulation.",
"datePublished": "2023-08-01",
"url": "https://questionsmedicales.fr/article/37600706",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.3389/fendo.2023.1192670"
}
},
{
"@type": "ScholarlyArticle",
"name": "Intraoperative physician assessment of bone: correlation to bone mineral density.",
"datePublished": "2023-03-31",
"url": "https://questionsmedicales.fr/article/37000208",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1007/s00198-023-06729-3"
}
},
{
"@type": "ScholarlyArticle",
"name": "Influence of bone density on stability in TBW.",
"datePublished": "2023-11-15",
"url": "https://questionsmedicales.fr/article/37968632",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1186/s12891-023-07007-3"
}
},
{
"@type": "ScholarlyArticle",
"name": "[Bone mineral density in vegetarians and vegans].",
"datePublished": "2023-04-17",
"url": "https://questionsmedicales.fr/article/37432709",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.33029/0042-8833-2023-92-3-69-78"
}
},
{
"@type": "ScholarlyArticle",
"name": "Phthalates and bone mineral density: a systematic review.",
"datePublished": "2022-11-12",
"url": "https://questionsmedicales.fr/article/36369032",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1186/s12940-022-00920-5"
}
}
],
"breadcrumb": {
"@type": "BreadcrumbList",
"itemListElement": [
{
"@type": "ListItem",
"position": 1,
"name": "questionsmedicales.fr",
"item": "https://questionsmedicales.fr"
},
{
"@type": "ListItem",
"position": 2,
"name": "Composés hétérocycliques",
"item": "https://questionsmedicales.fr/mesh/D006571"
},
{
"@type": "ListItem",
"position": 3,
"name": "Composés hétéromonocycliques",
"item": "https://questionsmedicales.fr/mesh/D006573"
},
{
"@type": "ListItem",
"position": 4,
"name": "Azirines",
"item": "https://questionsmedicales.fr/mesh/D001389"
},
{
"@type": "ListItem",
"position": 5,
"name": "Aziridines",
"item": "https://questionsmedicales.fr/mesh/D001388"
},
{
"@type": "ListItem",
"position": 6,
"name": "1,1',1''-Phosphoryltriaziridine",
"item": "https://questionsmedicales.fr/mesh/D013721"
}
]
}
},
{
"@type": "MedicalWebPage",
"name": "Article complet : 1,1',1''-Phosphoryltriaziridine - Questions et réponses",
"headline": "Questions et réponses médicales fréquentes sur 1,1',1''-Phosphoryltriaziridine",
"description": "Une compilation de questions et réponses structurées, validées par des experts médicaux.",
"datePublished": "2025-05-17",
"inLanguage": "fr",
"hasPart": [
{
"@type": "MedicalWebPage",
"name": "Diagnostic",
"headline": "Diagnostic sur 1,1',1''-Phosphoryltriaziridine",
"description": "Comment diagnostiquer une exposition au Triethylenephosphoramide ?\nQuels tests sont utilisés pour évaluer la toxicité ?\nQuels symptômes indiquent une intoxication ?\nY a-t-il des marqueurs biologiques spécifiques ?\nComment évaluer les effets à long terme ?",
"url": "https://questionsmedicales.fr/mesh/D013721?mesh_terms=Bone+Density#section-diagnostic"
},
{
"@type": "MedicalWebPage",
"name": "Symptômes",
"headline": "Symptômes sur 1,1',1''-Phosphoryltriaziridine",
"description": "Quels sont les symptômes d'une exposition aiguë ?\nPeut-on avoir des symptômes neurologiques ?\nQuels symptômes digestifs peuvent apparaître ?\nY a-t-il des symptômes cutanés associés ?\nComment les symptômes évoluent-ils dans le temps ?",
"url": "https://questionsmedicales.fr/mesh/D013721?mesh_terms=Bone+Density#section-symptômes"
},
{
"@type": "MedicalWebPage",
"name": "Prévention",
"headline": "Prévention sur 1,1',1''-Phosphoryltriaziridine",
"description": "Comment prévenir l'exposition au Triethylenephosphoramide ?\nQuelles formations sont nécessaires pour les travailleurs ?\nQuels sont les protocoles de sécurité recommandés ?\nComment gérer les déchets contenant ce composé ?\nY a-t-il des recommandations pour les laboratoires ?",
"url": "https://questionsmedicales.fr/mesh/D013721?mesh_terms=Bone+Density#section-prévention"
},
{
"@type": "MedicalWebPage",
"name": "Traitements",
"headline": "Traitements sur 1,1',1''-Phosphoryltriaziridine",
"description": "Quel est le traitement principal en cas d'intoxication ?\nDes antidotes existent-ils pour ce composé ?\nComment traiter les symptômes neurologiques ?\nQuelles mesures de soutien sont recommandées ?\nY a-t-il des traitements spécifiques pour les effets chroniques ?",
"url": "https://questionsmedicales.fr/mesh/D013721?mesh_terms=Bone+Density#section-traitements"
},
{
"@type": "MedicalWebPage",
"name": "Complications",
"headline": "Complications sur 1,1',1''-Phosphoryltriaziridine",
"description": "Quelles complications peuvent survenir après exposition ?\nY a-t-il des risques de cancer associés ?\nComment les complications sont-elles surveillées ?\nLes complications peuvent-elles être réversibles ?\nQuels sont les effets à long terme possibles ?",
"url": "https://questionsmedicales.fr/mesh/D013721?mesh_terms=Bone+Density#section-complications"
},
{
"@type": "MedicalWebPage",
"name": "Facteurs de risque",
"headline": "Facteurs de risque sur 1,1',1''-Phosphoryltriaziridine",
"description": "Qui est le plus à risque d'exposition ?\nQuels environnements augmentent le risque ?\nY a-t-il des facteurs génétiques impliqués ?\nComment l'âge influence-t-il le risque ?\nLes antécédents médicaux jouent-ils un rôle ?",
"url": "https://questionsmedicales.fr/mesh/D013721?mesh_terms=Bone+Density#section-facteurs de risque"
}
]
},
{
"@type": "FAQPage",
"mainEntity": [
{
"@type": "Question",
"name": "Comment diagnostiquer une exposition au Triethylenephosphoramide ?",
"position": 1,
"acceptedAnswer": {
"@type": "Answer",
"text": "Le diagnostic repose sur l'historique d'exposition et des tests biologiques spécifiques."
}
},
{
"@type": "Question",
"name": "Quels tests sont utilisés pour évaluer la toxicité ?",
"position": 2,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des tests sanguins et des analyses d'urine peuvent détecter des métabolites toxiques."
}
},
{
"@type": "Question",
"name": "Quels symptômes indiquent une intoxication ?",
"position": 3,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les symptômes incluent des nausées, des vomissements et des troubles neurologiques."
}
},
{
"@type": "Question",
"name": "Y a-t-il des marqueurs biologiques spécifiques ?",
"position": 4,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, des marqueurs comme les enzymes hépatiques peuvent indiquer une toxicité."
}
},
{
"@type": "Question",
"name": "Comment évaluer les effets à long terme ?",
"position": 5,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des suivis réguliers et des évaluations cliniques sont nécessaires pour détecter des effets chroniques."
}
},
{
"@type": "Question",
"name": "Quels sont les symptômes d'une exposition aiguë ?",
"position": 6,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les symptômes aigus incluent des maux de tête, des vertiges et des troubles respiratoires."
}
},
{
"@type": "Question",
"name": "Peut-on avoir des symptômes neurologiques ?",
"position": 7,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, des symptômes neurologiques comme des convulsions peuvent survenir."
}
},
{
"@type": "Question",
"name": "Quels symptômes digestifs peuvent apparaître ?",
"position": 8,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des nausées, vomissements et diarrhées sont fréquents après exposition."
}
},
{
"@type": "Question",
"name": "Y a-t-il des symptômes cutanés associés ?",
"position": 9,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des éruptions cutanées et des irritations peuvent se manifester après contact."
}
},
{
"@type": "Question",
"name": "Comment les symptômes évoluent-ils dans le temps ?",
"position": 10,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les symptômes peuvent s'aggraver avec le temps si l'exposition se poursuit."
}
},
{
"@type": "Question",
"name": "Comment prévenir l'exposition au Triethylenephosphoramide ?",
"position": 11,
"acceptedAnswer": {
"@type": "Answer",
"text": "Utiliser des équipements de protection individuelle et suivre les protocoles de sécurité."
}
},
{
"@type": "Question",
"name": "Quelles formations sont nécessaires pour les travailleurs ?",
"position": 12,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des formations sur la manipulation sécurisée des produits chimiques sont essentielles."
}
},
{
"@type": "Question",
"name": "Quels sont les protocoles de sécurité recommandés ?",
"position": 13,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les protocoles incluent des procédures d'urgence et des contrôles d'exposition réguliers."
}
},
{
"@type": "Question",
"name": "Comment gérer les déchets contenant ce composé ?",
"position": 14,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les déchets doivent être éliminés selon les réglementations en vigueur pour les produits toxiques."
}
},
{
"@type": "Question",
"name": "Y a-t-il des recommandations pour les laboratoires ?",
"position": 15,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les laboratoires doivent avoir des systèmes de ventilation et des douches de sécurité."
}
},
{
"@type": "Question",
"name": "Quel est le traitement principal en cas d'intoxication ?",
"position": 16,
"acceptedAnswer": {
"@type": "Answer",
"text": "Le traitement principal est l'élimination de l'exposition et le soutien symptomatique."
}
},
{
"@type": "Question",
"name": "Des antidotes existent-ils pour ce composé ?",
"position": 17,
"acceptedAnswer": {
"@type": "Answer",
"text": "Il n'existe pas d'antidote spécifique, le traitement est symptomatique."
}
},
{
"@type": "Question",
"name": "Comment traiter les symptômes neurologiques ?",
"position": 18,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les symptômes neurologiques peuvent nécessiter des médicaments anticonvulsivants."
}
},
{
"@type": "Question",
"name": "Quelles mesures de soutien sont recommandées ?",
"position": 19,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des soins de soutien, comme l'hydratation et le monitoring, sont essentiels."
}
},
{
"@type": "Question",
"name": "Y a-t-il des traitements spécifiques pour les effets chroniques ?",
"position": 20,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les traitements des effets chroniques incluent la réhabilitation et le suivi médical."
}
},
{
"@type": "Question",
"name": "Quelles complications peuvent survenir après exposition ?",
"position": 21,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des complications incluent des troubles hépatiques, rénaux et neurologiques."
}
},
{
"@type": "Question",
"name": "Y a-t-il des risques de cancer associés ?",
"position": 22,
"acceptedAnswer": {
"@type": "Answer",
"text": "Une exposition prolongée peut augmenter le risque de certains cancers."
}
},
{
"@type": "Question",
"name": "Comment les complications sont-elles surveillées ?",
"position": 23,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des examens médicaux réguliers et des tests de fonction organique sont nécessaires."
}
},
{
"@type": "Question",
"name": "Les complications peuvent-elles être réversibles ?",
"position": 24,
"acceptedAnswer": {
"@type": "Answer",
"text": "Certaines complications peuvent être réversibles avec un traitement précoce."
}
},
{
"@type": "Question",
"name": "Quels sont les effets à long terme possibles ?",
"position": 25,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les effets à long terme peuvent inclure des troubles chroniques et des déficits fonctionnels."
}
},
{
"@type": "Question",
"name": "Qui est le plus à risque d'exposition ?",
"position": 26,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les travailleurs dans l'industrie chimique et les laboratoires sont les plus à risque."
}
},
{
"@type": "Question",
"name": "Quels environnements augmentent le risque ?",
"position": 27,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les environnements de travail mal ventilés et non sécurisés augmentent le risque."
}
},
{
"@type": "Question",
"name": "Y a-t-il des facteurs génétiques impliqués ?",
"position": 28,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des facteurs génétiques peuvent influencer la susceptibilité à la toxicité."
}
},
{
"@type": "Question",
"name": "Comment l'âge influence-t-il le risque ?",
"position": 29,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les personnes âgées peuvent être plus vulnérables aux effets toxiques."
}
},
{
"@type": "Question",
"name": "Les antécédents médicaux jouent-ils un rôle ?",
"position": 30,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, des antécédents de maladies hépatiques ou rénales augmentent le risque."
}
}
]
}
]
}
Childhood and adolescence are critical periods of bone mineral acquisition. Children on anticoagulation (AC) might have an increased risk for reduced bone mineral density (BMD). Risk factors for impai...
To evaluate BMD in children on AC and characterize the risk factors of low BMD, including VK and Vitamin D (VD) status....
Single-center cross-sectional study of clinical, biochemical, and densitometric parameters. Assessment of VK surrogate parameters included ucOC and matrix gla protein (MGP)....
A total of 39 children (4-18 years; 12 females) receiving AC were included, 31 (79%) on VK antagonists and 8 (21%) on direct oral anticoagulants. Overall, BMD was decreased for both the lumbar spine (...
Our data indicate BMD reduction in pediatric patients on AC. Although AC-related factors did not predict reduced BMD, low BMI and pubertal stages represented important risk factors. Awareness of risk ...
This study evaluated the intraoperative physician assessment (IPA) of bone status at time of total knee arthroplasty. IPA was highly correlated with distal femur and overall bone mineral density. When...
Intuitively, intraoperative physician assessment (IPA) would be an excellent measure of bone status gained through haptic feedback during bone preparation. However, no studies have evaluated the ortho...
Seventy patients undergoing TKA by 3 surgeons received pre-operative DXA. Intraoperatively, bone quality was assessed on a 5-point scale (1 excellent to 5 poor) based on tactile feedback to preparatio...
The mean (SD) age and BMI were 65.8 (7.6) years and 31.4 (5.1) kg/m...
IPA is highly correlated with local (distal femur) and overall BMD. This study supports the International Society for Clinical Densitometry position that surgeon concern regarding bone quality should ...
Osteoporosis is a common disease that leads to a reduction in bone density and increases the risk of fractures. Stable surgical treatment is particularly important for these fractures. The aim of this...
The number of vegetarians and vegans is increasing each year. In this regard, studies of the quality of diets that exclude slaughter foods, as well as their impact on human health, are becoming more a...
Exposure to endocrine disruptors, such as phthalates, may impact bone mineral density (BMD) through a variety of mechanisms. Studies of phthalate exposure and BMD in humans are scarce....
To synthesize published data on the association between phthalate metabolites and BMD in humans and to provide methodological suggestions for future research....
A single investigator searched PubMed for relevant studies, including observational studies of phthalate exposure and BMD in children and postmenopausal women. Twelve studies were screened with 5 meet...
In one prospective study among postmenopausal women, higher levels of monocarboxyoctyl phthalate (MCOP) and monocarboxynonyl phthalate (MCNP) were significantly associated with lower BMD among nonuser...
Studies among postmenopausal women provide suggestive evidence of an association between urinary phthalate metabolite concentration and decreased BMD. Results from studies of childhood BMD are inconcl...
Sagittal spinal malalignment often leads to surgical realignment, which is associated with major complications. Low bone mineral density (BMD) and impaired bone microstructure are risk factors for ins...
A retrospective, cross-sectional study of patients who underwent lumbar fusion for degeneration was conducted. The vBMD of the lumbar spine was assessed by quantitative computed tomography. Bone biops...
A total of 172 patients (55.8% female, 63.3 years, BMI 29.7 kg/m...
Sagittal malalignment is associated with lower lumbar vBMD and trabecular microstructure. Lumbar vBMD was significantly lower in patients with malalignment. These findings warrant attention, as malali...
The aims of the study were to determine the mean trabecular bone score (TBS) of postmenopausal Taiwanese women and to analyze the value of TBS in predicting osteoporosis....
A total of 1,915 postmenopausal women with lumbar spine and hip bone mineral density (BMD) and spine TBS were enrolled from a single medical center into this study. The women's BMD and TBS were measur...
The average age of the women was 62.5 ± 9.1 years (range, 25.7-93.7 years). The mean TBS was 1.300 ± 0.086 (range, 1.015-1.596). The TBS was weakly and negatively correlated with body mass index ( r =...
Bone mineral density and TBS can be used in combination to predict osteoporosis in a greater number of postmenopausal Taiwanese women. Because the incidence of osteoporosis is the highest among older ...
Children with haemophilia (CwH) have lower bone mineral density in the spine (trabecular bone) than healthy children. There are few studies focusing on bone mineral density in long bones (cortical bon...
To evaluate bi-laterally the distal third of radius and midshaft tibias using quantitative ultrasound (QUS) and assess the speed of sound (SoS)....
A cross-sectional study where 91 CwH and 91 age-matched healthy boys were included. Joint evaluation was determined with the Haemophilia Joint Health Score 2.1 and SoS values. The Z scores were measur...
Ninety-one CwH (haemophilia A) were evaluated (26 mild form, 26 moderate, and 39 severe). Most patients were treated with on-demand factor replacement and had higher total HJHS scores according to sev...
There was diminished cortical bone density in radius and tibias of CwH compared to healthy controls. Changes predominated in tibias, more frequently affected according to the severity of haemophilia. ...
Low bone mineral density (BMD) and dementia commonly co-occur in older individuals, with bone loss accelerating in patients with dementia due to physical inactivity and poor nutrition. However, uncert...
In a prospective population-based cohort study, BMD at the femoral neck, lumbar spine, and total body and the trabecular bone score (TBS) were obtained using dual-energy X-ray absorptiometry in 3,651 ...
Among the 3,651 participants (median age 72.3 ± 10.0 years, 57.9% women), 688 (18.8%) developed incident dementia during a median of 11.1 years, of whom 528 (76.7%) developed Alzheimer disease (AD). D...
In conclusion, participants with low femoral neck and total body BMD and low TBS were more likely to develop dementia. Further studies should focus on the predictive ability of BMD for dementia....
Bone health in primary ovarian insufficiency (POI) is under-investigated. We assessed patients with spontaneous POI for vertebral fractures (VFs) and related parameters of bone health....
70 cases with spontaneous POI (age 32.5 ± 7.0 years) and an equal number of controls were assessed for BMD, TBS, and VFs. BMD at the lumbar-spine (L1-L4), left hip, non-dominant forearm, and TBS (iNsi...
BMD at the lumbar-spine, hip and forearm was reduced by 11.5%, 11.4% and 9.1% in POI as compared to controls (P < 0.001). Degraded or partially degraded microarchitecture on TBS was observed in 66.7% ...
Thus, lumbar-spine osteoporosis, impaired TBS and VFs were present in 35.7%, 66.7% and 15.7% of patients with spontaneous POI in their early third decade. This indicates need for rigorous investigatio...
